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Abstract Severe malaria in pregnancy is a large con-
tributor to maternal morbidity and mortality. Intravenous
quinine has traditionally been the treatment drug of choice
for severe malaria in pregnancy. However, recent ran-
domized clinical trials (RCTs) indicate that intravenous
artesunate is more efficacious for treating severe malaria,
resulting in changes to the World Health Organization
(WHO) treatment guidelines. Artemisinins, including ar-
tesunate, are embryo-lethal in animal studies and there is
limited experience with their use in the first trimester. This
review summarizes the current literature supporting 2010
WHO treatment guidelines for severe malaria in pregnancy
and the efficacy, pharmacokinetics, and adverse event data
for currently used antimalarials available for severe malaria
in pregnancy. We identified ten studies on the treatment of
severe malaria in pregnancy that reported clinical out-
comes. In two studies comparing intravenous quinine with
intravenous artesunate, intravenous artesunate was more
efficacious and safe for use in pregnant women. No studies
detected an increased risk of miscarriage, stillbirth, or
congenital anomalies associated with first trimester expo-
sure to artesunate. Although the WHO recommends using
either quinine or artesunate for the treatment of severe
malaria in first trimester pregnancies, our findings suggest
that artesunate should be the preferred treatment option for
severe malaria in all trimesters.
Key Points
Intravenous artesunate is the most efficacious
treatment for severe malaria, but data are limited on
its use in pregnancy
No associations have been reported between
artemisinin use in humans and increased risk of
miscarriage, stillbirth, or congenital anomalies
The 2010 WHO guidelines recommend using either
quinine or artesunate for the treatment of severe
malaria in first trimester pregnancies
Current data suggest that WHO treatment guidelines
should be changed to recommend artesunate as the
preferred treatment option for severe malaria in
pregnancy during all three trimesters
1 Introduction
An estimated 54.7 million pregnancies occurred in areas of
stable Plasmodium falciparum malaria transmission, and
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an additional 70.5 million pregnancies occurred in areas of
low transmission or areas with only Plasmodium vivax
malaria in 2007 [1, 2]. Malaria in pregnancy is associated
with higher rates of parasitemia, severe anemia, hypogly-
cemia, and acute pulmonary edema than malaria in non-
pregnant women [3]. Malaria in pregnancy is a major
contributor to morbidity and mortality, resulting in an
estimated 100,000 neonatal deaths and 10,000 maternal
deaths annually [4, 5]. Severe malaria is defined as acute
malaria with major signs of organ dysfunction and/or high
levels of parasitemia [3]. Pregnant women living in areas
of unstable transmission are at higher risk of severe malaria
and corresponding mortality [6]. Pregnant women in such
areas have a three-times higher risk of severe malaria than
do non-pregnant women [7]. Despite the substantial mor-
bidity and mortality associated with severe malaria in
pregnancy, pregnant women are often excluded from ran-
domized trials of treatment drugs due to ethical concerns
about the safety of these drugs for pregnant women and
their fetuses [8].
The management of severe malaria in pregnancy
needs to weigh the risks and benefits of treating malaria
and the potential for adverse events for the pregnancy
and fetus. Early treatment is critical because fever and
illness of the mother are major risk factors for adverse
pregnancy outcomes beyond the effects of the malaria
parasite itself. The World Health Organization (WHO)
guidelines stress prioritizing the life of the mother when
treating severe malaria [9]. In choosing an appropriate
therapy, one must weigh the known risks to the life of
the mother compared with the uncertain risks of the
treatment on the fetus.
This review summarizes the current literature available
on the treatment of severe malaria in pregnancy. We
review the data used to support 2010 WHO treatment
guidelines for severe malaria in pregnancy and assess
whether the current data support these guidelines.
2 Literature Review Methodology
In order to identify all studies of the treatment of severe
malaria in pregnancy, we conducted a review informed by
the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines [10]. To identify
all articles on severe malaria in pregnancy, we searched
MEDLINE and Embase with the terms (‘severe malaria’
OR ‘complicated malaria’ OR ‘falciparum malaria’ OR
‘cerebral malaria’) AND ‘pregnancy’ AND (‘treatment’
OR ‘artemisinin’ OR ‘artesunate’ OR ‘artemether’ OR
‘quinine’) published before August 2014. We limited our
search to English language articles. We also reviewed the
references of key publications to ensure that all relevant
literature was included in the review. We reviewed all of
the literature that included the treatment of severe malaria
in pregnancy. We included studies that reported the specific
drug treatments pregnant women received and reported
outcomes by drug regimen. Outcomes of interest included
measures of efficacy in pregnancy, safety, and pharmaco-
kinetics. The full results of our search are outlined in
Fig. 1.
Data are scarce on treatment of severe malaria in
pregnancy, so this review presents data on the drugs cur-
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Fig. 1 Results of the systematic
review of studies of the
treatment of severe malaria in
pregnancy
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pregnancy from studies of the treatment of uncomplicated
malaria in pregnancy and the treatment of severe malaria in
adults. This information was included in order to fully
describe the safety and efficacy of the currently used
therapies for the treatment of severe malaria in pregnancy.
We used data from both the systematic review of the
treatment of severe malaria in pregnancy and the key
studies of uncomplicated malaria in pregnancy and severe
malaria in adults to inform our recommendations.
3 Severe Malaria
3.1 Definition
The WHO defines severe P. falciparum malaria as a patient
with P. falciparum asexual parasitemia with evidence of
organ dysfunction (Fig. 2). The WHO definition of severe
malaria applies for all patients, including pregnant women.
A case of uncomplicated malaria can rapidly progress to
severe malaria due to either delayed treatment or treatment
failure.
3.2 Epidemiology of Severe P. falciparum Malaria
in Pregnancy
Pregnant women have a three-times higher risk of severe
malaria than non-pregnant women [7, 11]. Before the
introduction of malaria control programs in Western
Thailand, 1 % (5/500) of pregnant women died of malaria
in a year [12]. The clinical presentation of severe malaria
varies by age and pregnancy status, with adults presenting
with hyperparasitemia, jaundice, and renal insufficiency
more often than children [13]. In a malaria epidemic in
India, severe anemia and cerebral malaria were more
common in pregnant women with severe malaria than in
non-pregnant women with severe malaria [20 % (5/45)
versus 4 % (10/243), and 76 % (34/45) versus 33 % (80/
243); p value \0.05], respectively [14]. Pregnant women
with malaria are also at increased risk of hypoglycemia,
acute respiratory distress syndrome (ARDS) [15], and hy-
perparasitemia [3] than non-pregnant women. In a review
of severe malaria in pregnancy in the Asia Pacific region
(227 women in eight studies) [14, 16–22], the median
mortality rate was 39 % but ranged from 8 to 100 % [6].
This wide range is related to the broad WHO definition of
severe malaria: the lowest mortality was reported in preg-
nant women whose only sign of severity was hypoglyce-
mia. By contrast, all women with renal failure died [6].
There are limited mortality data from sub-Saharan Africa,
but the percentage of maternal deaths attributed to malaria
may be very similar between low- and high-transmission
areas [4, 23, 24]. Two studies conducted in Sudan noted no
maternal deaths among the pregnant women with severe
malaria [25, 26]. In a retrospective case review of all
maternal deaths 1985–1999, severe malaria was responsi-
ble for up to one-third of all maternal deaths in Sudan, a
low-transmission setting [27]. Severe malaria accounted
for 10 % of all deaths in an autopsy study of maternal
mortality in Mozambique [24], and, similarly, was attrib-
uted to 9 % of maternal deaths in Western Kenya (a high-
transmission setting) [28]. In addition to risk of death for
the mother, infants born to women with clinical malaria
infections late in pregnancy are at higher risk of early
neonatal death during infancy [29, 30]. Young maternal
age is an independent risk factor for severe malaria, with
older age providing some protection [4]. Obstetric help
should be sought, as severe malaria usually precipitates
premature labor [31]. Even when the mother survives, there
remains an increased risk of miscarriage and stillbirth,
prematurity, and low birth weight for the fetus [6, 7, 9, 29,
32–34].
WHO Deﬁnion of Severe Malaria
The WHO deﬁnes severe P. falciparum malaria as a paent with P. falciparum
asexual parasitemia and one of the following clinical features: 
• Impaired consciousness or coma, prostraon, failure to feed, mulple 
convulsions, acidoc breathing, circulatory collapse, clinical jaundice 
with evidence of other vital organ dysfuncon, hemoglobinuria, 
abnormal spontaneous bleeding, and/or pulmonary edema.
Laboratory ﬁndings can include: 
• Hypoglycemia  (blood glucose <2.2 mmol/l or <40 mg/dl), metabolic 
acidosis (plasma bicarbonate <15 mmol/l), severe normocyc anemia 
(Hb <5 g/dl), hemoglobinuria, hyperparasitemia (>2%/100,000 per µl in low 
intensity transmission areas or >5%/ 250,000 per µl in areas of high stable 
malaria transmission), and renal impairment (serum creanine >265 
µmol/l) [57].  
Fig. 2 World Health
Organization (WHO) definition
of severe malaria. Hb
hemoglobin
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3.3 Epidemiology of Severe P. vivax Malaria
P. vivax malaria is not as benign as previously thought;
recent data suggest that there is an increasing burden of
morbidity and mortality due to P. vivax malaria in pregnant
women [11, 35–38]. In high-prevalence areas such as
regions in India, Myanmar, Asia Pacific, and South
America, there have been cases where the P. vivax infec-
tions behaved more like P. falciparum [39–41]. P. vivax
infections may trigger immune responses that could lead to
potentially lethal clinical episodes independently or syn-
ergistically with other conditions or co-infections [42].
This inflammatory potential, in combination with P. vivax-
induced hemolysis, increased red cell fragility, dysery-
thropoiesis, and retention of erythrocytes within the spleen
contributes to severe anemia [43–45]. Localized exacer-
bations in the lung microvasculature have been proposed to
cause ARDS [46]. Jaundice, renal failure, severe throm-
bocytopenia, acidosis, and, rarely, coma have also been
reported in association with P. vivax [39]. In pregnancy, P.
vivax malaria was reported to be associated with moderate
anemia, but severe anemia could develop in pregnancy due
to P. vivax malaria [47–50]. However, severe anemia in
pregnancy may develop gradually via recurrent P. vivax
episodes, and may not be reported as severe malaria in
many settings. The burden of P. vivax malaria, and its
severe manifestations, has been complicated by the emer-
gence of resistance to chloroquine [39, 43].
The epidemiology of severe P. vivax malaria in pregnancy
is difficult to determine. In the search for this manuscript, only
four P. vivax-related maternal deaths were reported in the
published literature. A cohort of 4,300 women with P. vivax
malaria on the Thai-Myanmar border included one P. vivax-
related maternal death: a third gravid, moderate anemic
(known B-thalassemia trait) woman who was 36 weeks
pregnant died from ARDS 7 days after commencement of
treatment for P. vivax malaria (P. vivax-related malaria
mortality 23/100,000 live births) [51]. In a cohort from
Indonesia, 456 women were diagnosed with P. vivax malaria,
ten of whom had severe P. vivax disease. Two of these women
died; P. vivax-related maternal mortality 439/100,000 (2/
456) [52]. In a description of malaria-infected placentas from
Mandla district in India, the authors describe a woman with a
fairly high P. vivax parasitemia, jaundice, and severe anemia
who died before labor started [53].
4 Current Treatment Guidelines
4.1 World health organization treatment guidelines
In order to combat the burden of malaria in pregnancy, the
WHO Malaria Policy Advisory Committee (MPAC)
recommends a three-pronged approach, including the use
of long-lasting insecticide-treated nets, intermittent pre-
ventative therapy (IPT) by which pregnant women receive
a dose of sulphadoxine-pyrimethamine (SP) at each ante-
natal care visit after the first trimester, and effective case
management [54]. For pregnant women who are infected
with P. falciparum, the WHO recommends treatment with
artemisinin-based combination therapies (ACTs) during the
second and third trimesters [55]. Artemisinins are given in
combination with other antimalarial drugs to prevent the
development of drug resistance. The WHO does not rec-
ommend the use of ACTs in the first trimester unless there
is no alternative and the life of the woman is in danger [5].
Table 1 summarizes the current WHO 2010 treatment
guidelines for severe P. falciparum malaria in pregnancy. In
the treatment of severe malaria in pregnancy, saving the life
of the mother is the primary objective. Intravenous artesu-
nate has been shown to significantly reduce the risk of death
from severe malaria compared with intravenous quinine in
adults and children with severe malaria [20, 56]. In a study
of 1,461 adults, artesunate was associated with a 34.7 %
[95 % confidence interval (CI) 18.5–47.6] reduction in
mortality compared with quinine for the treatment of severe
malaria [20]. A similar study in 5,424 children found a
22.5 % (95 % CI 8.1–36.9) reduction in mortality associ-
ated with treatment with artesunate compared with quinine.
Therefore, the WHO guidelines recommend intravenous
artesunate in preference over quinine in the second and third
trimester for severe malaria. Quinine is associated with
recurrent hypoglycemia. However, in the first trimester, the
risk of hypoglycemia is lower and the uncertainties over the
safety of artemisinin derivatives is greater. The WHO rec-
ommends using either quinine or artesunate for the treat-
ment of severe malaria in first-trimester pregnancies, until
more evidence becomes available [57].
Although the WHO recommends artesunate as the pre-
ferred treatment for severe malaria in pregnancy, the USA,
through the Centers for Disease Control and Prevention
(CDC), recommends the use of quinidine (Figs. 2, 3).
Quinidine is associated with arrhythmias, and a recent case
series of patients hospitalized in the USA with malaria
noted that four of six patients receiving quinidine experi-
enced QT prolongation and two of six patients experienced
Torsades de Pointes, a life-threatening arrhythmia associ-
ated with QT prolongation [58].
The evidence used to support the WHO treatment
guidelines was based, in part, on a Cochrane review con-
ducted in 2007 [59], which was updated in 2012 [60].
Treatment with artesunate significantly reduced the risk of
death both in adults [relative risk (RR) 0.61, 95 % CI
0.50–0.75; 1,664 participants, five trials] and children (RR
0.76, 95 % CI 0.65–0.90; 5,765 participants, four trials)
[60]. Only one study in the systematic review, the South
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East Asian Quinine Artesunate Malarial Trial (SEAQUA-
MAT), enrolled pregnant women and presented results
stratified by pregnancy status [20]. In this large trial of
1,461 participants, 23 women in the artesunate arm and 26
in the quinine arm were pregnant at enrollment, but tri-
mester of pregnancy was not reported. Mortality among
pregnant women with severe malaria was 9 and 12 % [odds
ratio (OR) 0.75; 95 % CI 0.09–6.41] for artesunate and
quinine arms, respectively [20]. The WHO justified their
recommendation for the use of artesunate instead of qui-
nine despite limited data in pregnancy due to the large
reduction in mortality associated with artesunate and the
increased risk of hypoglycemia associated with the use of
quinine [57]. Treatment must not be delayed; if only one of
the drugs artesunate, artemether, or quinine is available,
then it should be started immediately. We conducted an
updated review of the literature using the same search
terms as Dondorp et al. [56] (‘malaria’, ‘cerebral malaria’,
‘severe malaria’, ‘complicated malaria’, ‘malaria falcipa-
rum’, ‘quinine’, and ‘cinchona alkaloids’ and ‘artemisinin’
and ‘artesunate’), but no new clinical trials including
pregnant women were identified.
4.1.1 World Health Organization Treatment Guidelines
for Severe P. vivax Malaria
Severe malaria has been assumed to be associated with P.
falciparum infection, but a recent review highlighted the
substantial burden of severe malaria due to P. vivax
infections [38]. While pregnant women were excluded,
the results of meta-analysis showed a similar incidence of
adult severe malaria due to P. vivax infections or P. fal-
ciparum mono-infection in adults [38]. In all trimesters of
pregnancy, the WHO recommended treatment for
uncomplicated P. vivax malaria is chloroquine, a total
dose of 25 mg base/kg body weight in 3 days [57]. In an
area with chloroquine-sensitive parasites, chemoprophy-
laxis with weekly chloroquine (500 mg phosphate or
300 mg base) prevented any recurrent P. vivax episodes in
pregnant women [61]. However, reports of chloroquine-
resistant parasites in pregnant women suggest that alter-
native treatment guidelines are needed to prevent repeated
dosing of an ineffective drug [62]. Many countries in the
Asia-Pacific region have changed the first-line treatment
of P. vivax malaria to ACTs. Quinine and clindamycin
Table 1 World Health Organization recommendations for the treatment of severe malaria in pregnancy
First trimester Second to third trimester
P. falciparum Either IV artesunate or quinine can be used IV artesunate should be used in preference to quinine
P. vivax Either IV artesunate or quinine
Suppressive prophylaxis with chloroquine until delivery
Post-delivery, women should receive radical treatment with
primaquine
IV artesunate should be used in preference to quinine
Suppressive prophylaxis with chloroquine until delivery









• Quinidine gluconate is the only parenterally administered anmalarial 
approved for the treatment of severe malaria in the United States. 
• If quinidine is unavailable or for paents who cannot tolerate quinidine, 
or with parasitemia >10% of baseline 48 hours aer iniang quinidine 
treatment, intravenous artesunate is available as an invesgaonal 
drug through the CDC [150].
• Quinidine is associated with syncope [151] and requires 
electrocardiographic monitoring, and in a study of paents with 
malaria, quinidine was associated with QT interval prolongaon [152]. 
United Kingdom
• The Royal College of Obstetricians recommends intravenous artesunate 
for the treatment of severe P. falciparum malaria in pregnancy. If 
intravenous artesunate is unavailable, intravenous quinine may be used 
[153].     
Fig. 3 Additional treatment
guidelines for the treatment for
severe malaria in pregnancy.
CDC Centers for Disease
Control and Prevention
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remain the treatment of choice for P. vivax malaria in the
first trimester [52].
For pregnant patients with severe P. vivax malaria, the
WHO recommends the same treatments as for severe P.
falciparum infections (Table 1) [57]. P. vivax has liver
stages (hypnozoites) that cause recurrent blood-stage
infections (relapses). Primaquine—the only drug effective
against liver stages—is contraindicated in pregnant women
because fetal red blood cells are susceptible to hemolysis
[63]. Pregnant women should receive suppressive prophy-
laxis with chloroquine until delivery, at which point they
can receive radical treatment with primaquine [61].
5 Summary of Drugs for Treatment of Severe Malaria
5.1 Artemisinins
The most efficacious drugs for treating severe malaria are
artemisinin-based compounds. Artemisinins, derived from
the plant Artemisia annua, have been used for centuries in
China to treat fever. Currently, three artemisinin com-
pounds are used to treat malaria: artesunate, artemether,
and dihydroartemisinin.
5.1.1 Safety of Artemisinins in Pregnancy
Despite their proven efficacy, artemisinins are embryotoxic
and teratogenic in animal studies [64]. Artesunate is toxic
to rat and rabbit embryos, with fetal reabsorption in rats
reported at low doses (28–223 mg/kg/day) given orally on
days 9–14 of gestation [55]. High rates of congenital
malformations, including bent and/or shortened long bones
and treatment-related heart defects, were observed in rat
litters [55]. Primate studies demonstrated similar embryo
toxicity, with 55 and 100 % embryo lethality for 12 and
30 mg/kg/d oral doses, respectively, after 12 days of
treatment [65]. In addition, observations of three live pri-
mate embryos from the 30 mg group noted reductions in
blood cells in the vasculature, and the cardiac chambers
were distended with thin walls [65]. The primary embry-
onic targets for artemisinins are the primitive erythroblasts
proliferating during gestational periods of 10–14 days in
the rat and 18–40 days in the monkey. In humans, this
corresponds to a sensitive period from post-conception
week 3 to approximately post-conception week 9 [65].
The findings from animal reproductive toxicology
studies and the dearth of human studies led the WHO to not
recommend the use of artemisinins in the first trimester of
pregnancy for uncomplicated malaria. The WHO recom-
mends that artesunate may be used to treat severe malaria
in the first trimester because of the high rates of mortality,
stillbirth, and miscarriage associated with severe malaria
[57]. Observational data on the safety and efficacy of ar-
temisinins in the first trimester of pregnancy are very
limited. A recent systematic review identified eight studies
of antimalarials from 1997 to 2013 that included first-tri-
mester pregnancies and a total of 35 studies including
pregnant women of any gestational age, but the vast
majority of patients had uncomplicated malaria [66]. The
systematic review identified 555 first-trimester exposures
to artemisinins in clinical trials [66], and an additional 945
women with a single malaria episode in the first trimester
were described along the Thai-Burma border, 92 of whom
were exposed to an artemisinin [9]. Neither the clinical
trials nor the large cohort study observed an increased risk
of adverse pregnancy outcomes associated with exposures
to artemisinins. Birth outcomes did not differ significantly
for women exposed to artesunate compared with quinine
and chloroquine during the first trimester, and artemisinins
were not associated with miscarriage after controlling for
maternal and malaria characteristics [9].
Studies in animals suggest that artesunate is a teratogen
when given alone or in combination with mefloquine [67,
68]. The limited safety data in humans have not shown any
increased risk of miscarriage, stillbirth, or congenital
anomalies associated with exposure during the first tri-
mester or later in pregnancy [9, 69–72]. Animal studies
suggest that, similar to artesunate, artemether is embryo-
toxic in rat models [73, 74]. The limited safety data in
humans have failed to find an association with artemether
exposure and increased risk of stillbirth, miscarriage, or
congenital anomalies [69, 75–77].
5.1.2 Artesunate
Artesunate is a water-soluble artemisinin derivative. The
drug is available orally in combination with other anti-
malarials, or in rectal and parenteral formulations used for
the treatment of severe malaria. Artesunate is associated
with faster parasite clearance than quinine because the drug
targets young circulating ring-stage parasites [78, 79].
Artesunate does not require a loading dose. For the treat-
ment of severe malaria, the WHO recommends 2.4 mg/kg
to be given immediately intravenously or by intramuscular
injection, with repeat doses at 12 and 24 h. Continued
injections can be given once daily as necessary.
A review of the literature identified three pharmacoki-
netic studies of artesunate in pregnant women. Pharma-
cology data suggest that pregnant women receiving oral
artesunate may have accelerated clearance rates of the
metabolite dihydroartemisinin compared with non-preg-
nant women [80, 81]. A single study of intravenous and
oral artesunate noted no significant differences in the
pharmacokinetics between pregnant women with malaria
compared with the same women in a healthy state after
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administration of intravenous artesunate. The same study
noted that pregnant women with malaria had significantly
higher drug exposure after receiving oral artesunate than
the same women when healthy and not pregnant [82].
Clinical data on the efficacy of artesunate in the treat-
ment of severe malaria in pregnancy are limited [9, 20, 52].
Only the SEAQUAMAT trial reported data on pregnant
women with severe malaria comparing artesunate with
quinine in a clinical trial setting. A systematic review by
Visser et al. [66] identified ten studies reporting outcomes
of pregnant women treated with artesunate. Artesunate is
associated with higher cure rates, lower gametocyte car-
riage, and lower treatment failure than quinine-based
therapies for the treatment of uncomplicated malaria in
pregnancy [69, 70, 72, 83, 84]. Our systematic review of
the literature identified two additional studies presenting
data on artesunate to treat severe malaria in pregnancy [9,
52]. Poespoprodjo et al. [52] found no statistically signif-
icant increased risk of poor maternal or fetal outcomes
associated with artesunate compared with quinine, and
noted than none of the ten women exposed to intravenous
artesunate in the first trimester had a miscarriage. McG-
ready et al. [9] noted that, although miscarriage rates were
very high for women with severe malaria in the first tri-
mester (58 %), there was no difference in the rates between
pregnant women treated with artesunate or quinine.
Artesunate is generally associated with better tolerabil-
ity than quinine [20, 83, 85]. The most important reported
side effect of artesunate is anaphylaxis, with an estimated
risk of approximately 1 in 3,000 patients. Additional
common minor side effects associated with intravenous
administration include dizziness, light-headedness, rash,
and taste alterations. Nausea, vomiting, and diarrhea have
been reported, but it is unclear whether these are associated
with artesunate or are symptoms of severe malaria [86].
Cardiotoxicity has been observed after administration of
high doses of artesunate [87]. Multiple studies in adults and
children suggest that up to 25 % of patients treated with
intravenous artesunate for severe malaria developed
delayed hemolytic anemia 7–31 days after treatment, but
the etiology is unknown [88–92].
5.1.3 Artemether
Artemether is a commonly used artemisinin for the treatment
of uncomplicated malaria when combined with lumefantrine
(marketed as Coartem). According to the WHO, artemether
can be used to treat severe malaria in pregnancy when ar-
tesunate is unavailable [57]. Artemether should be given at
3.2 mg/kg body weight intramuscularly at admission and
then 1.6 mg/kg body weight per day as needed. The paren-
teral formulation is oil based; data suggest that it is poorly or
erratically absorbed in this formulation [93].
A review of the literature identified four pharmacoki-
netic studies of artemether in pregnant women. All four
studies demonstrated that pregnant women have lower
concentrations of artemether and its metabolite dihyd-
roartemisinin than non-pregnant controls [94–97]. These
results suggest that further research is needed to identify
the correct oral dose of artemether for pregnant women to
decrease the likelihood of treatment failure and to prevent
resistance. No studies were identified that examined the
pharmacokinetics of artemether as an injection in pregnant
women, but, because it is oil based it is hypothesized that
absorption is erratic [93].
A systematic review of artemether for the treatment of
severe malaria, conducted in 2001 using data from seven
trials, noted that 14 % of those treated with artemether and
17 % of those treated with quinine died (OR 0.08, 95 % CI
0.62–1.02; p = 0.08), but none of the trials included
pregnant women [98–102]. The authors concluded that
artemether was equivalent to quinine for the treatment of
severe malaria [103]. The systematic review noted that
treatment with artemether was not associated with an
increased number of adverse events compared with qui-
nine, but artemether was associated with significantly faster
parasite clearance, hazard ratio (HR) 0.62 (95 % CI
0.56–0.69). An updated systematic review of the literature
by the authors failed to identify any studies published since
2001 that included results for pregnant women.
A systematic review of the treatment of malaria in preg-
nancy by Visser et al. identified 16 studies reporting preg-
nancy outcomes in women exposed to artemether–
lumefantrine (AL) or artemether for treatment of uncom-
plicated malaria [66, 69, 72, 75, 76, 94, 104–109]. An
additional systematic review of the use of artemether and AL
to treat uncomplicated malaria in pregnancy identified 1,103
reports of AL use in pregnancy [110]. Broadly, the efficacy
of artemether was non-inferior or superior to that of quinine.
Specifically, one study comparing quinine with artemether
combined with atovaquone–proguanil (A ? AP) saw much
higher day 63 cure rates in the A ? AP group than in the
quinine group [94.9 % (95 % CI 81.4–99.1) vs. 63.4 % (95
% CI 46.9–77.4) respectively] [109].
Intramuscular artemether is generally well tolerated,
with very few side effects reported [93, 111–113]. Pain and
swelling at the injection site is a common, mild side effect
[113]. Cardiotoxicity has been observed rarely, resulting in
arrhythmias such as ventricle tachycardia [87].
We identified two trials, both conducted in Vietnam, that
directly compared artemether with artesunate for treating
severe malaria in adults [114, 115]. Both trials excluded
women pregnant in their first trimester and did not report
results stratified by pregnancy status. One trial compared
four different regimens with no statistically significant
difference in mortality across the treatments. The mortality
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rates were 11.1 % (5/45) for intramuscular artemether,
17.6 % (9/51) for artemisinin suppositories, 10.2 % (6/49)
for intramuscular artesunate, and 17.6 % (5/30) for intra-
venous artesunate [114]. A second double-blind trial con-
ducted between 1996 and 2003 compared intramuscular
artesunate with intramuscular artemether for the treatment
of severe malaria. The trial reported 7 % (13/186) mor-
tality in the artesunate group and 13 % (24/184) mortality
in the artemether group; however, the results were not
statistically significant (p = 0.052). The authors concluded
that intramuscular artemether may not be the best arte-
misinin therapy for treating severe malaria because the
drug releases slowly and erratically compared with water-
soluble artesunate [115].
5.2 Quinine
Quinine was first discovered as a treatment for malaria in
the 17th century [85]. Quinine is available as oral or
intravenous preparations and reaches peak concentrations
1–3 h after administration [116]. Quinine attacks intra-
erythrocytic malaria parasites, and it has gametocytocidal
properties against P. vivax and Plasmodium malariae but
not P. falciparum [85]. The pharmacokinetic properties of
quinine vary by age of the patient and malaria status.
Unlike artemisinin-based therapies, quinine is not con-
sidered embryotoxic or teratogenic in studies of rats [117],
rabbits [55], dogs [55], or macaque monkeys [118]. The
primary safety concern for quinine in pregnancy is the
potential for auditory nerve damage [55]. Quinine expo-
sures during the first trimester were not associated with an
increased risk of congenital malformation in refugees along
the Thai-Burma border [9, 70]. One study reported an
increased risk of miscarriage and stillbirth associated with
first-trimester exposure to quinine compared with AL
[119]. Despite previous concerns, quinine at treatment
doses does not induce abortion or labor [18].
A literature review identified six studies of the phar-
macokinetics of quinine for treating uncomplicated malaria
in pregnancy [95, 120–123]. The results of these studies
varied in their findings, with some studies suggesting that
that was no difference in the metabolism of quinine
between pregnant and non-pregnant women [122], and
other studies suggesting that pregnant women metabolize
quinine faster than non-pregnant women, requiring further
research into the proper dosing for pregnancy.
Despite quinine being used for hundreds of years for the
treatment of severe malaria in pregnancy, the systematic
review identified only ten relevant studies [9, 14, 16, 19,
20, 25, 26, 52, 124, 125] (Tables 2, 3). Of concern, quinine
has been associated with a higher risk of hypoglycemia,
which can be fatal, than treatment with artemisinins [126].
A recent systematic review identified ten studies conducted
between 1997 and 2013 on the efficacy of quinine com-
pared with artemisinin-based therapies for the treatment of
uncomplicated malaria in pregnancy [66]. McGready et al.
[70] reported statistically significantly lower 63-day cure
rates for quinine when compared with mefloquine ? ar-
tesunate (67 vs. 98.2 %; p = 0.0001) for the treatment of
uncomplicated malaria [70]. Quinine ? clindamycin had
similar cure rates to those of artesunate, but significantly
higher rates of side effects [83]. Additional studies noted
very high mortality rates among pregnant women with
severe malaria: from 0 to 80 % for those treated with
intravenous quinine [16, 25].
Intravenous quinine is less well tolerated than intrave-
nous artesunate [83]. Mild to moderate cinchonism,
including tinnitus, headache, blurred vision, altered audi-
tory acuity, nausea, and diarrhea often arise after 3 days of
treatment [87]. Poor tolerability of oral quinine has been
linked to lower adherence and subsequent treatment fail-
ures in patients [127–129]. A study of the compliance with
artesunate compared with quinine ? tetracycline found
that non-pregnant patients who were taking artemisinins
were more likely to be compliant with treatment [adjusted
RR (aRR) 1.39, 95 % CI 1.15–1.68], and the reasons cited
for non-compliance were adverse drug reactions and for-
getting to take drugs [127]. Tinnitus is the most commonly
reported side effect in pregnant women [85]. Pregnant
women are also at risk for a rare triad of complications:
massive hemolysis, hemoglobinemia, and hemoglobinuria
[130]. Additional side effects include muscle necrosis and
sterile abscesses due to intramuscular injections. Dose-
related adverse events include cardiovascular symptoms
such as transient ventricular tachycardia, and gastrointes-
tinal and central nervous system disorders resulting from
excessive infusions [87].
5.3 Partner Drugs
After initial treatment for severe malaria with intravenous
quinine or artesunate, patients should receive oral regi-
mens. The WHO recommends either quinine ? clinda-
mycin for 7 days or an oral ACT for the treatment of
pregnant women [57], but the safety of these partner drugs
should also be considered [131]. Quinine ? clindamycin is
recommended by the WHO for the treatment of malaria in
the first trimester. Clindamycin, a common partner drug,
has been associated with abdominal side effects, including
nausea, vomiting, and diarrhea [132, 133]. However, a
more recent RCT comparing quinine ? clindamycin and
artesunate for the treatment of uncomplicated malaria in
pregnancy did not report abdominal side effects, but
women in the trial taking quinine ? clindamycin did
experience significantly higher rates of tinnitus than did the
artesunate group [83]. Because of relatively high rates of
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side effects and the high cost per treatment (US$18.50)
[83], quinine ? clindamycin may result in poor adherence
in resource-poor settings.
6 Special Considerations
6.1 HIV and Severe Malaria in Pregnancy
Pregnant women have the greatest burden of the mor-
bidity and mortality associated with co-infection with
HIV and malaria [134]. HIV infection is associated with a
greater risk of severe malaria [135, 136]. Despite this
large burden, very little information exists about interac-
tions between ACTs and antiretroviral therapy (ART) and
the optimal treatment options for severe malaria in
pregnant women with HIV. One study of the pharmaco-
kinetics of quinine in HIV-positive pregnant women noted
that quinine concentrations may be lower in women
receiving nevirapine-based ART [123]. The WHO rec-
ommends that HIV-infected patients receiving zidovudine
or efavirenz should avoid amodiaquine-containing ACT
regimens because of reports of hepatotoxicity [57]. A
review of the concurrent management of HIV in preg-
nancy recommends that women receiving highly active
antiretroviral therapy (HAART) regimens including pro-
tease inhibitors (PIs) and/or non-nucleotide reverse
transcriptase inhibitors (NNRTIs) receive quinine when
cardiac monitoring is available. Parenteral artesunate or
artemether should be used when quinine and cardiac
monitoring are not available because of an increased risk
of cardiotoxicity associated with quinine [137, 138].
Women receiving no PIs or NNRTIs may be treated with
either parenteral quinine or artesunate [139]. Current
clinical data suggest that artemether when co-adminis-
tered with PIs or NNRTIs may result in a reduction in the
active metabolite of artemether, but the clinical impor-
tance is unclear [137].
6.2 Rectal Administration of Antimalarial Drugs
for Severe Malaria in the Community
The WHO recommends rectal administration of artesunate
as a pre-referral treatment for severe malaria [57]. There
are currently no data comparing rectal administration with
intravenous and intramuscular injections of artemisinin
derivatives; therefore, the WHO guidance states that sup-
positories only be used for pre-referral treatment. Fur-
thermore, there are no studies of rectal administration of
artesunate to treat malaria in pregnancy. According to the
WHO, if referral is impossible, patients may be treated
with artesunate suppositories until able to receive oral
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trials of pre-referral rectal administration of artesunate
identified only one study. The study found a protective
effect in young children who received rectal artesunate
compared with placebo (RR 0.74, 95 % CI 0.59–0.93), but
older children and adults were at greater risk of death than
the placebo group (RR 2.21, 95 % CI 1.18–4.15) [140].
Despite these contradictory findings, it is critical to treat
malaria early, especially in pregnancy.
6.3 Drug Quality
Poor-quality antimalarials have important health conse-
quences, including the potential for treatment failure,
development of antimicrobial resistance, and serious
adverse drug reactions. Treatment with counterfeit oral
artesunate has led to deaths due to severe malaria [141].
Reports from surveys conducted in sub-Saharan Africa
(SSA) samples and south-east Asia indicate that orally
administered antimalarial drugs are commonly of poor
quality [142]. Nayyar et al. [143] reviewed published and
unpublished studies and found that 35 % (497/1,437) of
samples from south-east Asia failed chemical testing.
Using the same criteria, this analysis also reported that
35 % (796/2,297) of samples from SSA failed chemical
analysis. Substandard drugs fail to meet the specifications
set forth by a regulatory agency and as specified in a
standard pharmacopeia or the manufacturer’s dossier.
Most surveys of drug quality emphasize sampling from
licensed pharmacies and dispensaries, not hospitals or
even the informal, unregulated markets. WHO pre-quali-
fication process that includes dossier reviews, site
inspections, and recognition of approval by stringent
regulatory agencies are the methods used by donors for
assuring the quality of medicines, including antimalarials
[144]. One manufacturer of injectable artesunate, Guilin
Pharmaceuticals, achieved WHO pre-qualification status
in 2010 [145]. A multitude of methods are used to assess
the quality of medicines and can be implemented at the
health facilities and ports of entry [146]. Ensuring the
quality and safety of antimalarials is critical in the treat-
ment of severe malaria.
7 Discussion and Conclusions
Severe malaria (P. falciparum as well as P. vivax malaria)
in pregnancy presents an immediate danger to the life of
the mother and fetus, and therefore effective treatment
must be delivered immediately. Despite the importance of
malaria in pregnancy, we identified only ten studies that
presented treatment outcomes of pregnant women with
severe malaria, demonstrating a paucity of data. Multiple
studies have shown that artemisinin derivatives,
specifically artesunate, are more effective at treating severe
malaria than quinine [9, 20, 52, 56]. Others have reported
on the economic advantages of intravenous artesunate over
intravenous quinine [147, 148]. Despite concerns about the
signal from animal studies of the embryo-lethality and
teratogenicity of artemisinins, no studies have shown an
association between artemisinin exposures during preg-
nancy and increased risk of miscarriage, stillbirth, or con-
genital anomalies in humans [9, 75, 76]. Safety data
suggest a need for strong pharmacovigilance, especially
regarding the reported delayed hemolysis after treatment
with intravenous artesunate. As the use of intravenous ar-
tesunate expands, the potential to detect rare but severe
adverse events will increase with the proper surveillance.
Additionally, pharmacovigilance systems are necessary to
aid in combatting the threat of falsified and substandard
antimalarials [149].
Given the high morbidity and mortality associated with
severe malaria in pregnancy, additional research is needed
on the pharmacokinetics of intravenous and intramuscular
artemisinin derivatives in pregnancy. Multiple studies have
suggested that pregnancy and malaria infection alter the
metabolism of artemisinins, and therefore the ideal thera-
peutic dosages in pregnancy are unclear. Furthermore,
additional research is needed on the efficacy of pre-referral
use of rectal artesunate in pregnant women with severe
malaria.
The current evidence suggests that intravenous artesu-
nate should be used in preference to intravenous quinine
for the treatment of severe malaria in first-trimester preg-
nancies. We recommend that WHO guidelines consider
artesunate as the preferred treatment for severe malaria in
pregnancy during all three trimesters in order to ensure that
pregnant women receive the most efficacious treatment.
We also recommend that the US Food and Drug Admin-
istration (FDA) approve artesunate for the treatment of
severe malaria, therefore allowing the CDC to update its
treatment guidelines to recommend the most efficacious
treatment. Recommendations for the treatment of severe
malaria in pregnancy must balance efficacy with preven-
tion of serious adverse advents by incorporating new evi-
dence as it becomes available.
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